Denton, Texas – Pharmaceutical giant Novartis announced plans on Wednesday, February 25, 2026, to establish a new, state-of-the-art radioligand therapy (RLT) manufacturing facility in Denton, Texas. The $280 million investment, as reported by the Denton Record-Chronicle, marks a significant expansion of Novartis’s U.S. Operations and its commitment to advancing cancer treatment. This facility will be the company’s fifth RLT manufacturing site in the United States and its first in the state of Texas, bolstering the largest RLT manufacturing network in the country.
The new 46,000-square-foot facility, located in the 2100 block of Shady Oaks Drive, will focus on the production of radioligand therapies, a promising area of cancer treatment that utilizes radioactive isotopes to target and destroy cancer cells. Novartis anticipates the plant will start operations in 2028, serving patients throughout the Southern United States and expanding capacity as RLT expands into earlier treatment lines and additional tumor types. The project is part of Novartis’s broader $23 billion investment in U.S. Operations, demonstrating a long-term commitment to innovation and manufacturing within the country.
Expanding Access to Next-Generation Cancer Therapies
Radioligand therapy represents a significant advancement in precision medicine, offering a targeted approach to cancer treatment with potentially fewer side effects than traditional therapies like chemotherapy. According to Novartis, the Denton site will be “purpose-built” for RLT production, ensuring the highest standards of quality and safety. The company currently markets two RLTs – Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer – and has a pipeline of other anticancer radiopharmaceuticals in development. The need for rapid delivery of these therapies, due to the short half-life of the radioactive isotopes used, has driven Novartis to establish a geographically diverse network of manufacturing facilities.
Vas Narasimhan, CEO of Novartis, emphasized the potential of RLT to “revolutionize cancer care.” The addition of the Denton facility strengthens the company’s ability to meet growing demand and deliver these next-generation treatments with the speed and precision they require. The company received FDA approval to supply Pluvicto from a production plant in New Jersey in 2023 and added a facility in Indiana to its manufacturing network in 2024, demonstrating a proactive approach to scaling up production capacity. BioSpace reports that Novartis likewise began building a facility in California and expanding the Indiana plant in 2024.
Economic Impact and Environmental Considerations for Denton
The new Novartis facility is expected to create between 150 and 175 jobs in Denton, offering opportunities in bioengineering, advanced manufacturing, quality control, and operations. Governor Greg Abbott hailed the investment as bringing “good-paying jobs” to the region and reinforcing Texas’s position as a leading biotech hub. The project is also expected to stimulate economic growth in Denton and surrounding communities. But, the site’s location presents a unique challenge: it requires the cleanup of radioactive waste left behind by the previous occupant, U.S. Radiopharmaceuticals, which ceased operations in 2018.
City Manager Sara Hensley stated that the project will address the property’s environmental issues and return a defunct site to the tax rolls. The cleanup timeline has not yet been finalized, according to city spokesperson Dustin Sternbeck, but is a prerequisite for construction to begin. The site previously housed Trace Life Sciences, which also manufactured medical radioisotopes. This remediation process underscores the complexities of developing sites with a history of radioactive material handling, requiring careful planning and adherence to stringent safety regulations.
Addressing the Legacy of U.S. Radiopharmaceuticals
The presence of residual radioactive contamination at the Shady Oaks Drive location necessitates a comprehensive cleanup plan overseen by state health officials. The nature of the radioactive waste and the scope of the remediation efforts are currently under assessment. While the specifics of the cleanup process remain to be determined, it will likely involve the removal and safe disposal of contaminated materials, as well as thorough monitoring to ensure the site meets environmental standards. This process is crucial not only for the safe development of the Novartis facility but also for protecting the health and well-being of the surrounding community.
Novartis’s investment in Denton represents a significant opportunity for the city and the state of Texas. The company estimates the project will generate $280 million in investment, according to information provided to the city, and create numerous high-skilled jobs. The facility will contribute to the growing biotechnology sector in the Dallas-Fort Worth area and enhance access to innovative cancer treatments for patients in the Southern United States. The project also highlights the increasing importance of radioligand therapy as a promising new approach to cancer care.
The Growing Field of Radioligand Therapy
The development and manufacturing of radioligand therapies present unique challenges due to the short half-lives of the radioactive isotopes used. These isotopes decay rapidly, requiring efficient and timely delivery of the therapies to patients. This logistical complexity has driven pharmaceutical companies like Novartis to establish a network of geographically distributed manufacturing facilities, ensuring that treatments can reach patients quickly and effectively. The need for specialized facilities and expertise in handling radioactive materials also contributes to the high cost of RLTs, raising questions about accessibility and affordability.
The expansion of RLT into earlier treatment lines and additional tumor types is expected to further increase demand for these therapies. Novartis is actively investing in research and development to expand its RLT pipeline and explore new applications for this technology. The company’s commitment to building a robust manufacturing network is essential to meeting this growing demand and ensuring that patients have access to these potentially life-saving treatments. Novartis’s official press release details the company’s $23 billion investment in U.S. Operations, underscoring its dedication to innovation and manufacturing in the country.
Construction of the Denton facility is scheduled to begin this year, with full operational capacity expected by 2028. The project represents a significant milestone in the advancement of cancer care and a testament to the growing importance of radioligand therapy as a targeted and effective treatment option. The next key checkpoint will be the finalization of the environmental cleanup plan and the commencement of construction activities.
We encourage readers to share their thoughts on this development and its potential impact on cancer treatment in the comments below. Please also share this article with your networks to raise awareness of this important advancement in medical technology.
Related reading